Alternatives to caspofungin
FDA shortage status is active for caspofungin; 2 same-class SPL records are listed below for registry comparison only.
Brand: Cancidas
caspofungin class peers while FDA lists an active shortage
caspofungin (Cancidas) is on an FDA shortage listing while 2 other Echinocandin Antifungal SPL records remain in this registry peer set (class inventory 3). Labeled indication field for caspofungin: Caspofungin treats several types of fungal infections.
Top FAERS reaction fields for caspofungin total 1,649 reports across 10 reactions, set beside anidulafungin, micafungin. Counts are exposure-weighted submissions, not per-patient risk.
About caspofungin
Caspofungin is an antifungal medicine. It fights fungal infections in your body.
Used for: Caspofungin treats several types of fungal infections. It is used for presumed fungal infections in patients with fever and low white blood cell counts. Caspofungin also treats infections caused by Candida, such as infections in the blood, abdomen, and esophagus. It can also treat invasive aspergillosis when other medicines don't work or can't be tolerated.
2 Echinocandin Antifungal peers (wide set)
anidulafungin
RxEraxis
Eraxis treats candidemia and other Candida infections, like intra-abdominal abscesses and peritonitis. It can be used in adults and children 1 month and older. Eraxis also treats esophageal candidiasis (a Candida infection in the esophagus) in adults. However, Eraxis may not work as well for esophageal candidiasis, and the infection may come back.
micafungin
RxMycamine
Micafungin treats several types of Candida infections. These include infections in the blood, abdomen, and esophagus. It can also prevent Candida infections in stem cell transplant patients.
caspofungin vs anidulafungin & micafungin · FAERS reaction fields
FAERS top-reaction field "Lung infection" shows the widest count spread between caspofungin and anidulafungin, micafungin in this extract (200-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | caspofungin | anidulafungin | micafungin |
|---|---|---|---|
| Death | 223 | 81 | 127 |
| Lung infection | 200 | - | - |
| Fever | 196 | - | - |
| Blood infection | 193 | - | - |
| Severe blood infection leading to organ damage | 175 | - | - |
| Fever with low white blood cell count | 163 | - | - |
| Lungs can't provide enough oxygen | 132 | - | - |
| Failure of multiple organs | 129 | - | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
caspofungin shortage vs Echinocandin Antifungal peer index
Shortage status
FDA shortage listing is active for caspofungin (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for caspofungin while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for caspofungin: see also the generic vs brand label guide when reading Cancidas SPL strings.
Read our methodology - how this data is sourced, computed, and verified.